File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy

TitleA randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy
Authors
Issue Date2004
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ophtha
Citation
Ophthalmology, 2004, v. 111 n. 12, p. 2240-2245 How to Cite?
AbstractTo determine the efficacy of a combination of 5-fluorouracil and low-molecular-weight heparin (LMWH) to improve the outcome of surgery for established proliferative vitreoretinopathy (PVR). Double-masked, prospective, randomized, placebo-controlled clinical trial. Three tertiary-referral teaching hospital vitreoretinal surgical units. One hundred fifty-seven patients with established PVR (grade C, anterior or posterior) undergoing vitrectomy surgery. All patients underwent vitreoretinal surgery and silicone oil exchange with or without membrane peeling and/or retinectomy. Patients were randomly allocated to perioperative infusion with or without 5-fluorouracil (200 μg/ml) and LMWH (5 IU/ml) in Hartmann's solution for 1 hour. The primary outcome measure was defined as posterior retinal reattachment after removal of silicone oil without any reoperations at 6 months. Secondary outcome measures recorded were posterior retinal reattachment, localized/tractional retinal detachment, visual acuity, macular pucker, hypotony, glaucoma, keratopathy, and cataract. Removal of silicone oil and reoperations were also recorded. Overall, at 6 months 84% of patients had full retinal reattachment and 94% had stable posterior retinal reattachment. There was no significant difference in success in the primary outcome measure (56%, treatment group; 51%, placebo group; P = 0.59) or in secondary outcome measures or rates of complications. Secondary macular pucker occurred less often in the treatment group (6% vs. 17% at 6 months, P = 0.068). A perioperative infusion of combined 5-fluorouracil and LMWH does not significantly increase the success rate of vitreoretinal surgery for established PVR. © 2004 by the American Academy of Ophthalmology.
Persistent Identifierhttp://hdl.handle.net/10722/146324
ISSN
2015 Impact Factor: 6.75
2015 SCImago Journal Rankings: 4.745
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCharteris, DGen_HK
dc.contributor.authorAylward, GWen_HK
dc.contributor.authorWong, Den_HK
dc.contributor.authorGroenewald, Cen_HK
dc.contributor.authorAsaria, RHYen_HK
dc.contributor.authorBunce, Cen_HK
dc.date.accessioned2012-04-10T01:50:14Z-
dc.date.available2012-04-10T01:50:14Z-
dc.date.issued2004en_HK
dc.identifier.citationOphthalmology, 2004, v. 111 n. 12, p. 2240-2245en_HK
dc.identifier.issn0161-6420en_HK
dc.identifier.urihttp://hdl.handle.net/10722/146324-
dc.description.abstractTo determine the efficacy of a combination of 5-fluorouracil and low-molecular-weight heparin (LMWH) to improve the outcome of surgery for established proliferative vitreoretinopathy (PVR). Double-masked, prospective, randomized, placebo-controlled clinical trial. Three tertiary-referral teaching hospital vitreoretinal surgical units. One hundred fifty-seven patients with established PVR (grade C, anterior or posterior) undergoing vitrectomy surgery. All patients underwent vitreoretinal surgery and silicone oil exchange with or without membrane peeling and/or retinectomy. Patients were randomly allocated to perioperative infusion with or without 5-fluorouracil (200 μg/ml) and LMWH (5 IU/ml) in Hartmann's solution for 1 hour. The primary outcome measure was defined as posterior retinal reattachment after removal of silicone oil without any reoperations at 6 months. Secondary outcome measures recorded were posterior retinal reattachment, localized/tractional retinal detachment, visual acuity, macular pucker, hypotony, glaucoma, keratopathy, and cataract. Removal of silicone oil and reoperations were also recorded. Overall, at 6 months 84% of patients had full retinal reattachment and 94% had stable posterior retinal reattachment. There was no significant difference in success in the primary outcome measure (56%, treatment group; 51%, placebo group; P = 0.59) or in secondary outcome measures or rates of complications. Secondary macular pucker occurred less often in the treatment group (6% vs. 17% at 6 months, P = 0.068). A perioperative infusion of combined 5-fluorouracil and LMWH does not significantly increase the success rate of vitreoretinal surgery for established PVR. © 2004 by the American Academy of Ophthalmology.en_HK
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ophthaen_HK
dc.relation.ispartofOphthalmologyen_HK
dc.subject.meshAgeden_US
dc.subject.meshAntimetabolites - Therapeutic Useen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshFibrinolytic Agents - Therapeutic Useen_US
dc.subject.meshFluorouracil - Therapeutic Useen_US
dc.subject.meshHeparin, Low-Molecular-Weight - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRetinal Detachment - Complications - Drug Therapy - Surgeryen_US
dc.subject.meshSilicone Oils - Administration & Dosageen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVitrectomyen_US
dc.subject.meshVitreoretinopathy, Proliferative - Drug Therapy - Etiology - Surgeryen_US
dc.titleA randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathyen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, D: shdwong@hku.hken_HK
dc.identifier.authorityWong, D=rp00516en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.ophtha.2004.05.036en_HK
dc.identifier.pmid15582080-
dc.identifier.scopuseid_2-s2.0-9644259068en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-9644259068&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume111en_HK
dc.identifier.issue12en_HK
dc.identifier.spage2240en_HK
dc.identifier.epage2245en_HK
dc.identifier.isiWOS:000225512300015-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridCharteris, DG=7003299563en_HK
dc.identifier.scopusauthoridAylward, GW=7007021912en_HK
dc.identifier.scopusauthoridWong, D=7401536078en_HK
dc.identifier.scopusauthoridGroenewald, C=6601917086en_HK
dc.identifier.scopusauthoridAsaria, RHY=6603036104en_HK
dc.identifier.scopusauthoridBunce, C=7005268305en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats